| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2700 |
| Trial ID | NCT04905862 |
| Disease | Kidney Failure | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran |
| Co-treatment | Diagnostic Test: Immune response |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia |
| Recruitment status | Unknown |
| Title | Multi Center Study to Assess the Humoral and Cellular Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy |
| Year | 2021 |
| Country | Poland |
| Company sponsor | Medical University of Gdansk |
| Other ID(s) | COViNEPH-1 |
| Vector information | |||
|
|||
| Cohort1: Hemodialyzed patients | |||||||||
|
|||||||||
| Cohort2: Patients treated with peritoneal dialysis | |||||||||
|
|||||||||
| Cohort3: Patients without chronic kidney disease | |||||||||
|
|||||||||
| Cohort4: Kidney transplant recipients | |||||||||
|
|||||||||